Blog

A Recap of Pharma AI Trends in 2023

January 3, 2024

Share This Post

The Augmented Workforce

With the global AI healthcare market set to reach $208.2 billion by 2030, key developments were made in 2023 across Generative AI and the future of work. In industries with time consuming review and approval processes, like BioPharma, generative AI proved to be a tremendous asset.

Without a doubt, advanced AI technologies are reimagining the future of medical writing and giving rise to an augmented workforce. Historically, medical writers have been faced with inefficient, monotonous processes and have been seeking a solution to save time and ensure accuracy. Enter generative AI, which uses Large Language Models (LLMs) and advanced machine learning to create human-like text, pulling from existing data and experiences to generate new content.

In addition, generative AI technologies can automate parts of the clinical document landscape. This allows medical writers to be more productive and efficient, while helping to pass strict regulatory requirements – saving time and costs caused by human error. AI technologies can summarize large amounts of data, explain analysis in-depth and can model and scale human expertise at levels that have not been achieved before.

The Rise of LLM and GenAI

2023 was the year of Generative AI, with LLMs and advanced machine learning techniques taking center stage. While the introduction of this technology was swift across the general population, careful considerations (like data security and transparency) were needed for implementations across BioPharma. Reviewing data security, transparency, and collaboration practices are paramount.

It seemed like there were new headlines surrounding GenAI every day in 2023. Between product launches and new ways of utilizing AI technologies, implementation of this tech became the new norm. Open AI’s ChatGPT soared to 100 million users in two months, representative of the technology’s triumph. Generative AI witnessed a surge in investments, especially in AI-enabled drug discovery, as illustrated by Novartis‘ latest strategic investment in Yseop.

Other GenAI news from the last year included developments in the EU AI Act, Amazon’s support for generative AI startups, and Samsung’s response to ChatGPT data leak. Tim Martin, Executive VP of Product & Development at Yseop, shared insights on the EU AI Act in Forbes. The discussion revolved around mitigating potential harmful effects, prioritizing human-centric and trustworthy AI, and Yseop’s contribution to enhancing human efficiency and fairness.

Graphs from Accenture's "Technology Vision 2023 for Biopharma"

Supporting Your AI Goals in 2024

Looking to 2024, Yseop remains committed to supporting content automation and GenAI transformation goals across life sciences. Learn more about our strategic collaborations, award recognition, and more by subscribing to our newsletter here.

Make sure to join Tim Martin as he looks at the fascinating world of generative AI, machine learning, and innovation by subscribing to the AI Uncovered podcast here. From exploring the transformative power of AI in medical writing to reviewing the ramifications of LLMs on regulated industries, tune in for insightful discussions with industry leaders.

Yseop’s Generative AI

It’s important to recognize that AI is more than just a tool. It has the ability to learn and make decisions based on content it has access to. With that, integrating technology into the workplace is most effective when done in a meaningful way. AI should be considered as a powerful amplifier or ally, rather than a replacement. As the leader in generative AI, Yseop changes the way content automation solutions are delivered with a human-centric, AI platform. Yseop Copilot is reimagining the future of work for pharmaceutical companies.

To learn more about Yseop Copilot, start your free automated content generation trial here. For more information on how we can help your organization, please contact hello@yseop.com.